Glimepiride USP
CGMP deviations.
14,806 recalls, newest first
CGMP deviations.
CGMP deviations.
CGMP deviations.
Failed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product monitoring.
Sub-potent drug: assay test result below specifications at 9-month timepoint.
Chemical Contamination: FDA testing found Presence of methanol
Chemical Contamination: FDA testing found Presence of methanol
CGMP deficiencies: Product manufactured at the same site where FDA testing found Presence of methanol in other products.
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations